A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.

Lyubynska, Natalya; Gorman, Matthew F; Lauchle, Jennifer O; Hong, Wan Xing; Akutagawa, Jon K; Shannon, Kevin; Braun, Benjamin S

Lyubynska, Natalya; Gorman, Matthew F; Lauchle, Jennifer O; Hong, Wan Xing; Akutagawa, Jon K; Shannon, Kevin; Braun, Benjamin S.

Affiliation

Lyubynska N; Department of Pediatrics, University of California, San Francisco, CA 94158, USA.

Sci Transl Med ; 3(76): 76ra27, 2011 Mar 30.

Article in En | MEDLINE | ID: mdl-21451123

Subject(s)

Benzamides/therapeutic use; Diphenylamine/analogs & derivatives; Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors; Mutation; Myeloproliferative Disorders/drug therapy; Proto-Oncogene Proteins p21(ras)/genetics; Animals; Benzamides/pharmacology; Cell Differentiation/drug effects; Diphenylamine/pharmacology; Diphenylamine/therapeutic use; Extracellular Signal-Regulated MAP Kinases/genetics; Extracellular Signal-Regulated MAP Kinases/metabolism; GTP-Binding Proteins/genetics; GTP-Binding Proteins/metabolism; Humans; MAP Kinase Signaling System/drug effects; Mice; Mice, Inbred C57BL; Myeloproliferative Disorders/pathology; Myeloproliferative Disorders/physiopathology; Myxovirus Resistance Proteins; Neoplasms/drug therapy; Neoplasms/pathology; Neoplasms/physiopathology; Random Allocation; Recombinant Fusion Proteins/genetics; Recombinant Fusion Proteins/metabolism; raf Kinases/genetics; raf Kinases/metabolism

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Benzamides / Proto-Oncogene Proteins p21(ras) / Mitogen-Activated Protein Kinase Kinases / Diphenylamine / Mutation / Myeloproliferative Disorders Type of study: Clinical_trials Limits: Animals / Humans Language: En Year: 2011 Type: Article

Fulltext

XML

PubMed Links

Search on Google